A novel gene therapy targeting Alzheimer’s disease will be evaluated in a Phase 1 clinical trial led by the University of California San Diego School…
Biogen and its Japanese partner Eisai announced Oct. 22nd an unexpected reversal—pharmaceutical giant Biogen said it will pursue US Food and Drug Administration approval for…
AbbVie terminated a clinical trial of its intravenously administered antibody, designed to slow the progression of Progressive Supranuclear Palsy (PSP), as it failed to show…
The Alzheimer’s Association gave $6 million to the University of California, Davis, to fund its participation in the U.S. POINTER study, a landmark effort to…
After a review of the clinical data, sponsors Amgen and Novartis have concluded that the potential benefit for participants in a Alzheimer’s disease program did…
Kerwin Research Center and Memory Care focuses on the care, evaluation and treatment of memory loss and dementia due to Alzheimer’s disease and other memory…
Weak microglia may constitute a link between two hallmarks of Alzheimer’s disease—clumps of amyloid- β protein and tangles of tau protein. Microglia, the brain’s primary…
A Lund University Study confirms that a simple blood test can reveal whether there is accelerating nerve cell damage in the brain. The researchers analyzed…
University of Chicago researchers engaged in preclinical research have redeemed amyloid precursor protein (APP), a contributor to Alzheimer’s disease, as an unlikely hero by uncovering…
University of South Florida-Led preclinical study helps uncovered promising therapeutic target for Alzheimer’s disease. Researchers have known that Apolipoprotein E (apoeE) is a major genetic…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
